Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm

Published:2019-05 Issue:3 Volume:13 Page:1935-1942
ISSN:1871-4021
Container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews
language:en
Short-container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Author:

Bin Hussain Azza Khalifa,Abdelgadir Elamin,Rashid Fauzia,Al Haj Abeer,Thadani Puja,Bashier Alaaeldin M.K.

Publisher

Elsevier BV

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference59 articles.

1. Arteriosclerosis and diabetes;Joslin;Ann. Clin. Med.,1927

2. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Emerging Risk Factors;Lancet,2010

3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33);Lancet,1998

4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34);Lancet,1998

5. 10-year follow-up of intensive glucose control in type 2 diabetes;Holman;N Engl J Med,2008

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin attenuates white matter injury in neonatal mice through activating NRF2/HO-1/NF-κB pathway;International Immunopharmacology;2024-11

2. Clinical application of Momordica charantia (Bitter Melon) for reducing blood sugar in type 2 diabetes mellitus;International Journal of Nutrition;2023-10-19

3. First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists;Annals of Internal Medicine;2022-10

4. One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus;Diabetes Therapy;2021-04-30

5. The Current and Potential Therapeutic Use of Metformin—The Good Old Drug;Pharmaceuticals;2021-02-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3